FDA's PEPFAR Tentative Approval Pathway Sets GMP Benchmark for ARV Manufacturers Seeking Global Access

For antiretroviral manufacturers targeting procurement under PEPFAR, FDA's tentative approval pathway functions as a de facto quality gate, one that has shaped ARV supply chains across resource-constrained markets since 2004. Understanding its mechanics is now a baseline competency for QA directors and regulatory affairs leads at any firm with global ambitions in HIV therapeutics.

The pathway sits within FDA's Center for Drug Evaluation and Research (CDER), which reviews marketing applications for both single-entity and fixed-combination ARV drug products intended for distribution outside the United States. PEPFAR procurement is restricted exclusively to products granted tentative approval or full approval by CDER, a hard eligibility boundary that makes regulatory readiness inseparable from market access strategy. The FDA's Office of Global Policy and Strategy (OGPS) coordinates agency-wide PEPFAR activity, with the PEPFAR Coordinator serving as the primary interface for drug firms entering the review process.

Two draft guidance documents are currently in circulation and warrant close attention from regulatory submissions teams. The first addresses eligibility for a barrier-to-innovation waiver under the Prescription Drug User Fee Act (PDUFA) for single-entity and fixed-combination ARV NDAs. The second provides application recommendations specifically for ARV products intended for PEPFAR procurement. Both documents signal FDA's intent to maintain rigorous review standards while accommodating the formulation complexity common in fixed-dose combination regimens, a tension that manufacturers must resolve at the dossier stage, not during review.

CDER also maintains a publicly accessible PEPFAR database, updated to a mobile-friendly interactive platform as of January 2022, listing every approved and tentatively approved ARV eligible for procurement. For QA leads, the database offers a practical benchmarking tool: the approval history of each listed product reflects the documentation standards and chemistry, manufacturing, and controls (CMC) expectations that CDER has accepted under this program. As of December 2018, FDA had approved its 200th HIV/AIDS therapy under PEPFAR, a volume that underscores the program's scale and the consistency of its review framework.

Firms seeking to enter the PEPFAR review process should direct initial inquiries to fdapepfar@fda.hhs.gov, with CDER's International Program serving as the operational point of contact for application-stage engagement.

The measurable threshold for market participation remains unchanged: tentative or full CDER approval is the non-negotiable condition for PEPFAR procurement eligibility.

Source: FDA What's New: Drugs RSS Feed via fda.gov, 22 May 2026.